Competing approaches to drug pricing in the 2024 election

The future of drug pricing policies in the US hinges on the outcome of the 2024 election, with the Democratic and Republican candidates presenting distinct approaches. Vice President Kamala Harris aims to expand upon the Biden administration’s existing policies, while former President Donald Trump’s stance remains less defined.

Harris has pledged to broaden the scope of Medicare drug price negotiations, a key achievement of the Biden presidency, to include more medications and benefit a wider population. She intends to utilize the resulting savings to fund an ambitious new proposal for long-term at-home care coverage under Medicare. This signifies a commitment to building upon the current administration’s efforts to lower drug costs and expand access to care.

In contrast, Trump has offered fewer specifics on his drug pricing plans. While he has campaigned on lowering prescription costs, his approach remains largely unclear. This lack of clarity leaves voters with uncertainty about the future of drug pricing policy under a potential Trump administration. The contrasting approaches of the two candidates underscore the significance of this issue in the upcoming election and its potential impact on the affordability and accessibility of medications for Americans.